| Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. | |
| | |
MedLine Citation:
|
PMID: 17725413 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The response to pegylated interferon (pegIFN) plus ribavirin (RBV) as treatment of chronic hepatitis C virus (HCV) infection is lower in HIV-coinfected than in HCV-monoinfected patients and could be due to suboptimal RBV dosing and/or insufficient duration of therapy in prior trials. In a prospective, multicenter, open, comparative trial, HCV/HIV-coinfected patients received pegIFN plus weight-based RBV for 48 or 72 weeks (HCV genotypes 1 and 4) and 24 or 48 weeks (HCV genotypes 2 and 3). Use of didanosine was not allowed. Out of 389 patients included in the trial, 61% were infected by HCV-1/4 and 67% had serum HCV-RNA >500,000 IU/ml. Sustained virological response (SVR) was achieved by 49.6%, significantly higher in HCV-2/3 than HCV-1/4 (72.4% vs. 35%; p < 0.0001). A high drop-out rate in the longer treatment arms precluded obtaining definitive conclusions about the efficacy of prolonging therapy. Premature treatment discontinuations due to serious adverse events occurred in 8.2%. Infection with HCV-2/3, lower baseline HCV-RNA, and negative HCV-RNA at week 12 were all independent predictors of SVR in the multivariate analysis. The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4. |
| | |
Authors:
|
Marina Núñez; Celia Miralles; Miguel Angel Berdún; Elena Losada; Koldo Aguirrebengoa; Antonio Ocampo; Piedad Arazo; Manuel Cervantes; Ignacio de Los Santos; Isabel San Joaquín; Santiago Echeverría; María José Galindo; Victor Asensi; Pablo Barreiro; Julio Sola; Juan José Hernandez-Burruezo; Josep Maria Guardiola; Miriam Romero; Javier García-Samaniego; Vincent Soriano; |
Related Documents
:
|
17032413 - Impact of liver steatosis on the antiviral response in the hepatitis c virus-associated... 15986873 - Pegylated interferon alpha-2a with or without ribavirin in hcv/hiv coinfection: partial... 9764363 - Sexual and mother-to-child transmission of the human immunodeficiency virus type 1: a r... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: AIDS research and human retroviruses Volume: 23 ISSN: 0889-2229 ISO Abbreviation: AIDS Res. Hum. Retroviruses Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-08-29 Completed Date: 2007-12-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8709376 Medline TA: AIDS Res Hum Retroviruses Country: United States |
Other Details:
|
Languages: eng Pagination: 972-82 Citation Subset: IM; X |
Affiliation:
|
Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiviral Agents / therapeutic use* CD4 Lymphocyte Count Female HIV* HIV Infections / complications*, drug therapy, virology Hepacivirus / drug effects Hepatitis C, Chronic / complications, drug therapy*, virology Humans Interferon Alfa-2a / therapeutic use* Interferon Alfa-2b / therapeutic use Male Polyethylene Glycols / therapeutic use* Prospective Studies Ribavirin / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a; 99210-65-8/Interferon Alfa-2b |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART e...
Next Document: No observable correlation between central nervous system side effects and EFV plasma concentrations ...